Loading...

MCRB SERES THERAPEUTICS INC Management Changes 8-K Filing

SRS

MCRB

SERES THERAPEUTICS INC

(MCRB)

2026 8-K

Financial Results Update

Annual Meeting Scheduled

Financial Results Announced

Management Changes

Financial Update

Cost Reduction Plan

Financial Statements

Financial Statements

Stockholder Approvals

Financial Results

Management Change

Board Appointment

Corporate Update

Financial Update

Stock Price Notice

Business Sale Approved

SER-155 Study Results

Financial Disclosure

Asset Purchase Agreement

Asset Purchase Agreement

Financial Results Announcement

Delisting Notice

Annual Meeting Approval

Financial Results Announcement

Appointment of CFO

Annual Meeting Announcement

Financial Results Announcement

Regulation FD Disclosure

Bylaws Amendments

Financial Results Announcement

Resignation of Director

Financial Results Announcement

Amendment to Restated Certi...

Annual Meeting of Stockholders

Financial Results Announcement

Credit Agreement and FDA Ap...

Financial Results Announcement

Appointment of Director

External Links:

On February 27, 2026, Seres Therapeutics appointed Richard N. Kender as Interim CEO, with new roles for Matthew Henn and Kelly Brady effective March 2, 2026. Kender will have a base salary of $520,000 and a potential signing bonus of $250,000, while Henn's salary increases to $505,000 with a $230,000 retention bonus; Brady's salary will be $475,000 with similar bonuses.

AI Assistant

SERES THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.